Home»Exposition»Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF

Novartis PARAGON-HF analyses suggest Entresto® benefit beyond HFrEF

0
Shares
Pinterest Google+

EAST HANOVER, N.J., Nov. 17, 2019 /PRNewswire/ — Entresto (sacubitril/valsartan) demonstrated greatest benefit in HFpEF patients with ejection fractions adjacent to HFrEF, compared to valsartan1 Entresto, compared to valsartan, demonstrated reduced risk in total heart failure…

Previous post

Prospects of Smart Cities: Digital Determines Future

Next post

Interim analysis from EMPRISE real-world study shows Jardiance® decreased risk of hospitalization for heart failure compared with DPP-4 inhibitors and GLP-1 receptor agonists